×
FILLY Study – Apellis Pharmaceuticals Inc.

FILLY Study – Apellis Pharmaceuticals Inc.

A Phase II, Multicentre, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients with Geographic Atrophy (GA).

Participants are randomised to 1 or 2 monthly treatment or no treatment.

Trial Registry Number: NCT02503332

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment